Samsung Biologics confirmed that the Seoul High Court has ruled in the company's favour, granting an injunction prohibiting industrial action across all nine core stages of the manufacturing process at its Songdo campus.
Lonza and Qurient, a clinical-stage biopharmaceutical company, has announced an exclusive license agreement for the use of Qurient’s cyclin-dependent kinase 7 (CDK7) inhibitors for dual-payload antibody-drug conjugate (ADC) applications.
Antibody-drug conjugates (ADCs) have transformed oncology therapeutics by combining the selectivity of monoclonal antibodies with the potency of highly cytotoxic small-molecule drugs. Rongrong Li, senior principal scientist, WuXi AppTec discusses.
Sterling Pharma Solutions has announced completion of an additional, large-scale GMP manufacturing suite at its dedicated bioconjugation facility in the UK, which will double capacity, as well as increasing the scale of manufacturing to 500L.
Teresa Barata, PhD, chief scientific officer at FairJourney Bio, spoke to Olivia Friett, editor of European Pharmaceutical Manufacturer, about The Antibody Series, held on 16–18 September in Évora, Portugal.
Lonza has announced its Rapid Media Prototyping Service (RaMP), giving biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation and early development.
SGS has expanded its Saint-Benoît laboratory, a strategic site dedicated to pharmaceutical bioanalysis and drug development for the pharmaceutical and biotechnology industries.
Antibody-drug conjugates (ADCs) are advancing cancer treatment, but their success depends on early safety insights and informed toxicology strategies. Xiaoxiao Wang, Yan Zhang, Junli Zhao, WuXi AppTec explains.
